Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer
Trial details
- Registry ID
- NCT06463665
- Phase
- Phase 2
The FDA approved Docetaxel (Brand of drug is based on institutional procurement) on 14 May 1996.
Drug identity checked against registry records
Also recorded as Brand of drug is based on institutional procurement; Docecad; Taxotere; Taxotere®
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 1996-05-14Day | Docetaxel | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "NDA020449", "applicant_as_listed_by_fda": "SANOFI AVENTIS US", "brand_names": ["TAXOTERE"], "active_ingredients": ["DOCETAXEL"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "19960514", "matched_on": "drug name equals FDA sole active ingredient"} First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026 |